EUCTR2009-014580-39-DE进行中（未招募）不适用
A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients 18-65 years who have given written informed consent, with the following main inclusion criteria:
- •A clinical history of birch pollen induced allergic rhinoconjunctivitis of two years or more requiring treatment during the birch pollen season
- •Lack of adequate relief with symptomatic medication during the previous pollen season
- •Positive Skin Prick Test (SPT) response to Betula verrucosa (wheal diameter = 3 mm) currently performed or not older than 60 days before screening
- •Positive specific IgE against Betula verrucosa (IgE Class = 2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Uncontrolled or severe asthma (FEV1 < 70% of predicted value in spite of adequate pharmacologic treatment)
- •History of emergency visit or admission for asthma in the previous12 months
- •Previous treatment by immunotherapy with birch or tree pollen allergen within the previous 5 years
- •Exclusion criteria in accordance with contraindications in the SmPC of SLITonePLUS.
研究者
相似试验
进行中（未招募）
不适用
A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQEUCTR2008-006921-14-DEALK-Abelló Arzneimittel GmbH
进行中（未招募）
1 期
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer. - EXPERT-CHigh risk operable rectal adenocarcinomaMedDRA version: 13.1 Level: PT Classification code 10038038 Term: Rectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004707-38-GBRoyal Marsden NHS Trust164
已完成
不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magentic resonance imaging defined high risk rectal cancerRectal cancerCancerISRCTN99828560Royal Marsden NHS Foundation Trust (UK)164
进行中（未招募）
不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined poor risk rectal cancer. - EXPERT-CPoor risk operable rectal adenocarcinomaEUCTR2004-004707-38-SEProf David Cunningham164
尚未招募
不适用
Evaluating the efficacy of radiation therapy compared to surveillance in men with prostate cancer that has returned after surgery and negative Prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scan.Cancer - ProstateProstate cancerACTRN12622001478707The Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd100